NASDAQ:AMLN
$17.49
(2/9 12:02PM)
+0.9%
| Open | $17.68 |
Mkt Cap | $2.5 Billion |
| High | $17.79 |
52Wk High | $19.99 |
| Low | $17.29 |
52Wk Low | $7.89 |
| Volume | 650,216 |
Avg Vol 10D | 4.8 Million |
Ockham's Rating/Recommendation Summary
Rating specific information requires Premium Access.
Buy Now
or
Learn More about Ockham's Features and Services.
AMLN Revenue
As a value investing shop, we are interested in seeing how AMLN's revenues measure up against past performances. One easily understandable way of doing that is to compare Price to Sales per share levels over a given time frame. Assuming it is available, Ockham prefers to look at ten years of history (for this stock there are 9 years of history available) and we weigh recent years more heavily. This allows us to find weighted average historical high and low Price to Sales ratios, which give us a better idea of the stock's current underlying value. Using this method, we have established a high range for Price to Sales of 22.85x and the low end of the range at 11.24x.
With respect to these historically rational metrics, notice that the current Price to Sales per share ratio for AMLN of 3.21x is well below its normal historic Price to Sales levels. At a price of $17.16, AMLN is 82% below where we would expect to see it. Clearly, this stock looks undervalued compared to historical levels, at least on a Price to Sales basis. This will positively affect our analysis because it is rare to find a stock this far below historical norms, and we would expect some price appreciation to bring this metric back towards a more normal range.
AMLN Cash Earnings
Price to Cash Earnings analysis is inappropriate for this company due to an insufficient positive cash earnings history. Rather than calculating a potentially misleading Price to Cash Earnings analysis, we have chosen to give AMLN a neutral Price to Cash Earnings outlook at this time. However, we should point out that this metric is a significant element in Ockham’s methodology to analyzing the outlook for any company. Therefore, for AMLN, our assessment is now more dependent on the Price to Sales analysis, and investors should be cautious with a company with very limited, if any, positive cash earnings.
AMLN Dividends
When determining a company's future prospects for success, Ockham Research sees analysis of dividend payments as a key additional factor. Even though it isn't imperative for AMLN to shell out a dividend in order to receive a positive rating, it can be helpful to further our analysis. While we do like to see companies with healthy and growing dividends, it is not appropriate for all companies, especially those focused on growth. In this regard, we regard AMLN as neutral because we do not have historical data for this company's dividends. We will being incorporating this into our analysis as soon as that data is available.
Earnings Per Share at AMLN Were on the Docket at Seeking Alpha Wall St Breakfast
AMLN's earnings per share was discussed on Seeking Alpha Wall St Breakfast which means there is something significant going on. Profits are the metric we pay the most attention to in our methodology.
Based on our methodology, Amylin Pharmaceuticals, Incorporated should hold some appeal to value investors as we view it as Undervalued as of this week's report. With the price now up to $18.77, we may consider downgrading the stock's valuation coming into next week. The Motley Fool CAPS crowd believes this stock will perform generally in line with the benchmark, or in other words the crowd is neutral. Ranking all stocks in terms of news coverage offers some interesting data. In the case of AMLN, it is getting significantly more attention in recent news coverage than we are used to seeing. The latest news on AMLN has created quite a stir as the stock is trading $1.61 higher in today's session.
“… (PR) AMYLIN PHARMACEUTICALS (AMLN): Q4 EPS of -$0. 35 misses by $0. 05. Revenue of $186M (flat) vs. $219M. Shares -1. 6% AH. …”
Seeking Alpha Wall St Breakfast Looked for Alpha in Amylin Pharmaceuticals, Incorporated
Will Amylin Pharmaceuticals, Incorporated help you find that extra alpha your portfolio needs? Check what was said on Seeking Alpha Wall St Breakfast to see their take.
Based on our methodology, Amylin Pharmaceuticals, Incorporated should hold some appeal to value investors as we view it as Undervalued as of this week's report. With the price now up to $19.01, we may consider downgrading the stock's valuation coming into next week. The Motley Fool CAPS crowd believes this stock will perform generally in line with the benchmark, or in other words the crowd is neutral. Ranking all stocks in terms of news coverage offers some interesting data. In the case of AMLN, it is getting significantly more attention in recent news coverage than we are used to seeing. The latest news on AMLN has created quite a stir as the stock is trading $1.85 higher in today's session.
“… GD, HES, ITW, MNI, MWV, NYB, PX, ROK, SAP, SEIC, SII, SO, STJ, SWK, TEL, UAUA, UTX, VLO, WLP Notable earnings after Wednesday's close: ACF, AF, AMLN, BMC, CCI, CTXS, DRE, ETFC, ... …”
Closing Bell: What is Happening with Amylin Pharmaceuticals, Incorporated Now?
Amylin Pharmaceuticals, Incorporated is one of the thousands of companies that Ockham has news analytics on, and it was recently discussed on Closing Bell.
Take notice of the news on this stock because it is up $1.87 since the close of trading yesterday. When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Amylin Pharmaceuticals, Incorporated has actually sunk a bit in comparison to the others. Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards AMLN and think that it will generally perform in-line with the S&P 500. At present, Ockham has a valuation stance of Undervalued on AMLN, as we could see significant price appreciation based on current fundamentals like cash earnings and revenue. However, this stock has already had a pretty good week, making it less attractive to value investors at the current price.
“… They are buying stock in lily, AMYLIN and alkermes. Shares of mankind are getting a boost. They are waiting for a less than palm sized inhabl diabetes device. …”
Interested in AMLN? See What the Pundits Said on Closing Bell
The latest news from Closing Bell on AMLN is available through Ockham's news analytics platform RazorWire.
Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards AMLN and think that it will generally perform in-line with the S&P 500. At present, Ockham has a valuation stance of Undervalued on AMLN, as we could see significant price appreciation based on current fundamentals like cash earnings and revenue. However, this stock has already had a pretty good week, making it less attractive to value investors at the current price. When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Amylin Pharmaceuticals, Incorporated has actually sunk a bit in comparison to the others. Take notice of the news on this stock because it is up $2.21 since the close of trading yesterday.
“… AMYLIN getting an upgrade at citi. Come back to the wall. The main ev earnings, yahoo! Over $16, a couple of others are trading to the down side. …”
Squawk On The Street Discusses Higher Prices and Amylin Pharmaceuticals, Incorporated
An abnormally high price is obviously a joyous occasion for investors in that stock. See what Squawk On The Street was talking about for AMLN below.
Take notice of the news on this stock because it is up $1.91 since the close of trading yesterday. When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Amylin Pharmaceuticals, Incorporated has actually sunk a bit in comparison to the others. At present, Ockham has a valuation stance of Undervalued on AMLN, as we could see significant price appreciation based on current fundamentals like cash earnings and revenue. However, this stock has already had a pretty good week, making it less attractive to value investors at the current price. Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards AMLN and think that it will generally perform in-line with the S&P 500.
“… AMYLIN soaring 10%. Citi boosting its target from 27 to 14. And two new 52-week highs. Amer asourcebergen and sherwin williams painting the town red. > > breaking budget ... …”
Amylin Pharmaceuticals, Incorporated Was Talked About by Squawk On The Street
The latest news on Squawk On The Street in regards to AMLN came through on RazorWire recently.
Crowd sentiment is neutral from the millions of opinions submitted through Motley Fool CAPS, which suggests most investors on their platform believe Amylin Pharmaceuticals, Incorporated will perform just about the same as the index. As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, AMLN has been less covered in the news compared to the rest of our universe of stocks. Check the news on this stock because there is a catalyst that has allowed this stock to advance 15.92% today. We considered AMLN as Undervalued as of our latest report at $17.63. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise. That being said, the recent price appriciation does make it slightly less attractive to value investors as they may have missed the boat.
“… Lilly, AMYLIN are expected to hear from the fda on their similar once a week drug. Is your similar market advantage here, if indeed there is one, going to be very short lived? ... …”
After Hours Activity in AMLN is the Topic on Closing Bell
Something is causing Amylin Pharmaceuticals, Incorporated to be a little more active in post market trading, and it was covered by Closing Bell recently.
Take notice of the news on this stock because it is up $0.94 since the close of trading yesterday. In comparison to the other stocks that we follow, Amylin Pharmaceuticals, Incorporated has seen more discussion in relation to its normal ranking among the group. Be aware that the news sources we track are focusing on this stock more often these days. At present, Ockham has a valuation stance of Undervalued on AMLN, as we could see significant price appreciation based on current fundamentals like cash earnings and revenue. Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards AMLN and think that it will generally perform in-line with the S&P 500.
“… AMYLIN. It did hit a new high. That's AMYLIN PHARMACEUTICALS as we set ourselves up now for ebay and starbucks to the nasdaq stocks which do come without their earnings after ... …”
Heard on Squawk On The Street: CEO of AMLN Discussed
CEO's are the strategic leaders of their companies, so any mention of them will garner special interest from us.
Based on our methodology, Amylin Pharmaceuticals, Incorporated should hold some appeal to value investors as we view it as Undervalued. The Motley Fool CAPS crowd believes this stock will perform generally in line with the benchmark, or in other words the crowd is neutral. We noticed recently that in comparison to all other stocks we analyze in the news; AMLN has received less coverage from the financial media in business television and blogs.
“… Thank you very much, dan bradbury, AMYLIN pharmaceutical ceo. > > > coming up next hour on "the call," the ceo of another bio pharma company that is poised to have a ... …”
Squawk On The Street Discussed the Latest Development of Amylin Pharmaceuticals, Incorporated
News has broken via the television and viral blogs regarding AMLN, so investors should take an interest in learning what was said.
As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, AMLN has been less covered in the news compared to the rest of our universe of stocks. We consider AMLN as Undervalued at the current price of $15.80. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise. Crowd sentiment is neutral from the millions of opinions submitted through Motley Fool CAPS, which suggests most investors on their platform believe Amylin Pharmaceuticals, Incorporated will perform just about the same as the index.
“… AMYLIN up 35% over the past five years is being called a biotech stock in 2010 in part due to a diabetes drug that could be a big hit. It's still waiting got-ahead from the fda. …”
Notice a Discussion Covering AMLN Appeared Recently in the Financial News
The latest news from business television and influential blogs is always available through Ockham's RazorWire, and this news is in relation to Amylin Pharmaceuticals, Incorporated.
Crowd sentiment is neutral from the millions of opinions submitted through Motley Fool CAPS, which suggests most investors on their platform believe Amylin Pharmaceuticals, Incorporated will perform just about the same as the index. When looking at our entire coverage universe and ranking stocks by the attention they receive on RazorWire, it is clear that Amylin Pharmaceuticals, Incorporated has been talked about more than normal recently. We consider AMLN as Undervalued at the current price of $15.80. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise.
“… coming up -- AMYLIN, biotech. Daniel brad bury talking excusively to "squawk on the street. " > > > and white house considering new fees on banks. …”